ID: MRFR/HC/0679-CRR | May, 2017 | Region: Global | 102 pages | Cooked Research Reports
Global Lung Cancer Market Information, by Type (SCLC, NSCLC); by treatment (Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT), Laser therapy); by end users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast to 2023
Market Synopsis of Global Lung Cancer Market:
Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the cancers with NSCLC representing the remaining. The cure rates for the two types of lung cancers are different and the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage IV.
The global market of Lung Cancer is expected to reach USD 36929.8 million in 2023 from USD 15219.7 million in 2016 with a CAGR of 13.5% during the forecast period 2017-2023.
Global Lung Cancer Market, by Types, 2016 (%):
Some of the key players in this market are: F. Hoffmann-La Roche AG, Novartis, PFIZER INC, Merck & Co., Inc., BRISTOL-MYERS SQUIBB, ELI Lilly and Company, Sanofi and others.
Global Lung Cancer Market has been segmented on the basis of types which comprises of SCLC and NSCLC. On the basis of treatments it is segmented into Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy. On the basis of end users, it includes Hospitals & Clinics, Cancer Research Centers and Laboratories.
Regional Analysis of Global Lung Cancer Market: